---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-067670"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:11:28.571773+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q2 net loss narrows to $1.05M; evaluating strategic alternatives

## Summary
- Net loss from continuing operations $1.05M ($0.09/sh) vs $2.4M ($0.24/sh) in Q2 2023.
- License revenue from Mayne License Agreement fell 46.5% to $234K from $437K.
- Operating expenses decreased 8.1% to $2.7M; cash and equivalents $5.2M as of June 30.
- Company continues to evaluate strategic alternatives including M&A or asset sale; no assurance of outcome.

## SEC filing metadata
- accession: 0001213900-24-067670
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390024067670/0001213900-24-067670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390024067670/ea0211036-8k_therape.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-067670
- JSON: https://secwatch.observer/filing/0001213900-24-067670.json
- Plain text: https://secwatch.observer/filing/0001213900-24-067670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.